FDA Approves Abrysvo

 May 31, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.

“A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. “Abrysvo will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.”

PETG Media BottlesPETG Media Bottles

The FDA’s decision is based on the data from the pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). RENOIR is a global, randomized, double-blind, placebo-controlled study designed to assess the efficacy, immunogenicity, and safety of a single dose of the vaccinein adults 60 years of age and older. RENOIR has enrolled approximately 37,000 participants, randomized to receive RSVpreF 120 μg or placebo in a 1:1 ratio. The results were recently published in The New England Journal of Medicine. RENOIR is ongoing, with efficacy data being collected in the second RSV season in the study.

“This past RSV season demonstrated the serious consequences and potential health risks this virus poses for older adults,” said Edward E. Walsh, MD, Professor of Medicine, University of Rochester Medical Center, and principal RENOIR investigator. “Today’s FDA approval of Abrysvo recognizes significant scientific progress, and importantly helps provide older adults potential protection against RSV and an opportunity to improve community health by helping prevent the disease.”

RSV is a contagious virus and a common cause of respiratory illness worldwide.2 The virus can affect the lungs and breathing passages of an infected individual, potentially causing severe illness or death.3,4,5 In the U.S., the burden RSV causes in older adults is considerable. The severity of RSV disease can increase with age and comorbidities, such as chronic obstructive pulmonary disease, asthma, and congestive heart failure.6

Cell Factory Cell Factory

The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) will meet on June 21, 2023, to discuss recommendations for the appropriate use of RSV vaccines in older adults. Pending the outcome of this meeting, Pfizer anticipates supply availability in Q3 2023 ahead of the anticipated RSV season this fall.

Earlier this month, Pfizer reported positive top-line results from the Phase 3 study evaluating the safety and immunogenicity of Abrysvo coadministered with seasonal inactivated influenza vaccine (SIIV) in adults 65 years and older.7 Pfizer intends to publish these results in a peer-reviewed scientific journal. Earlier this month, Pfizer also announced it would be initiating multiple clinical trials evaluating RSVpreF in healthy children ages 2-5; children ages 5-18 with underlying medical conditions; adults ages 18-60 at high-risk due to underlying medical conditions; and adults ages 18 and older who are immunocompromised and at high-risk for RSV.8

Source: https://www.drugs.com/newdrugs/fda-approves-abrysvo-respiratory-syncytial-virus-vaccine-prevention-respiratory-syncytial-virus-rsv-6031.html

评论

发表评论

此博客中的热门博文

Material features of PETG media bottles

图片
  PETG media bottles   are a special packaging for storing various media, reagents, serum and other solutions, and it is also a product that scientific researchers have more contact with. The wide range of applications is mainly due to the superior properties of its materials. PETG is a transparent plastic that belongs to the non-crystalline copolyester. Serum needs to be stored in a low temperature environment. The use range of this material is -80°C to 60°C, which makes PETG media bottles fully meet the storage needs of serum. In addition, it has the following features: 1. High transparency, the light transmittance reaches 90%, which can reach the transparency of plexiglass; 2. It has stronger rigidity and hardness, excellent scratch resistance, impact resistance and toughness, which is close to or even exceeds that of polycarbonate (PC), and is suitable for injection molding, extrusion molding and extrusion blowing processing; 3. In terms of chemical resistance, oil resistance, weat
阅读全文

What are the common specifications of serum bottles

图片
  In biological laboratories, we often have to store various solutions and reagents. Thanks to the advantages of good performance, transparency, and temperature resistance, serum bottles have become "frequent visitors" in the laboratory. As a commonly used storage container, what are its common specifications?                      FuDau 60ml-Square-PETG-PET-Media-Bottles Common materials for serum bottles include PETG and PET, both of which have very good temperature resistance and transparency. In comparison, bottles made of PETG have more advantages in terms of barrier properties. If you want to pursue a better storage state of the solution, it is recommended to use a bottle made of PETG. There is a molded scale on the body of the bottle, we can clearly observe the capacity and state of the solution. The common specifications of this kind of container include 5ml/10ml/30ml/60ml/125ml/250ml/500ml/1000ml, etc., which are mostly used to store serum, culture medium, buffer, dis
阅读全文

Cell factory requirements for production raw materials

图片
Cell factories   are mainly used for large-scale cell culture. Cells have high requirements on the environment, such as temperature, humidity, osmotic pressure, pH value, etc. Therefore, this kind of   cell   consumables also has high requirements on raw materials. The first is transparency. In the process of cell culture, it is necessary to grasp the growth state of the cells at any time, and make corresponding adjustments according to the cell proliferation. Therefore, the raw materials of the cell factory must meet the requirements of transparency, so that it is convenient for researchers to observe the growth of cells. The second is the compatibility of materials. The raw materials of this consumable generally meet the requirements of USP Class VI medical polymer materials. Medical polymer materials refer to polymer materials used to manufacture human internal organs, external organs, pharmaceutical dosage forms and medical devices, and their sources include natural biopolymer mate
阅读全文